Thrombocytosis with acquired von Willebrand disease in an adolescent with sickle cell disease

Thrombocytosis is common in sickle cell disease and may contribute to vaso ‐occlusion. Hydroxyurea treats extreme thrombocytosis. Acquired von Willebrand disease should be considered prior to aspirin therapy. AbstractThrombocytosis is common in sickle cell disease and may contribute to vaso ‐occlusion. Hydroxyurea treats extreme thrombocytosis. Acquired von Willebrand disease should be considered prior to aspirin therapy.

Source: Clinical Case Reports - November 20, 2020 Category: General Medicine Authors: Marianne E. M. Yee, Glaivy Batsuli, Satheesh Chonat, Sunita Park Tags: CASE REPORT Source Type: research